ESMO 2024: Dr. Jonasch on implications of positive HIF-2α inhibitor data in ccRCC
"It clearly shows that blocking HIF-2α is a meaningful way of interacting with disease biology in clear cell renal cell carcinoma," says Eric Jonasch, MD.
In this video, Eric Jonasch, MD, discusses next steps and potential implications of findings from an ongoing phase 1/2 study (NCT05119335) of the investigational oral HIF-2α inhibitor NKT2152, which were presented at the 2024 European Society for Medical Oncology Annual Congress in Barcelona, Spain. Overall, data showed that NKT2152 demonstrated strong anti-tumor activity in patients with heavily pretreated advanced clear cell renal cell carcinoma.
Jonasch is a professor of genitourinary medical oncology at the University of Texas MD Anderson Cancer Center in Houston.
Video Transcript:
What are the next steps for this agent based on these findings?
It's clear this agent is active. The question now really would be, what would be an appropriate registrational strategy to move this agent forward as a potential treatment for patients with renal cell carcinoma? That's a matter of discussion at this point in time by the company, and they're going to be deciding on how to move forward.
What are the potential clinical implications of this research?
It clearly shows that blocking HIF-2α is a meaningful way of interacting with disease biology in clear cell renal cell carcinoma. It may be good to have more than 1 agent of the same class. We clearly need to learn much more though about which patients are most likely to respond, why does resistance occur, and what would be the best partners in terms of combination strategies for this agent.
This transcription has been edited for clarity.
